An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes

Neutral Protamine Hagedorn ◽

The Cost

PDB24 COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING

Value in Health ◽

10.1016/s1098-3015(10)75002-6 ◽

2009 ◽

Vol 12 (7) ◽

pp. A405-A406

Author(s):

E Suchankova ◽

T Doležal ◽

Z Pisarikova ◽

K Rychna ◽

D Bartaskova

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

Cost Effectiveness Analysis ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

DB1 EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH OUTCOMES

Value in Health ◽

10.1016/s1098-3015(11)73078-9 ◽

2010 ◽

Vol 13 (7) ◽

pp. A507

Author(s):

J Chang ◽

F Sun ◽

H Li

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Health Outcomes ◽

Insulin Aspart ◽

Basal Insulin ◽

Biphasic Insulin ◽

The Cost

PDB7 LONG TERM COST EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30/70 VERSUS INSULIN GLARGINE IN INSULIN NAÏVE PATIENTS WITH TYPE-2 DIABETES POORLY CONTROLLED ON ORAL HYPOGLYCEMIC AGENTS IN DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH, SWEDISH AND UK SETTINGS

Value in Health ◽

10.1016/s1098-3015(10)65950-5 ◽

2004 ◽

Vol 7 (6) ◽

pp. 736-737 ◽

Cited By ~ 1

Author(s):

M Lammert ◽

AJ Palmer ◽

S Roze ◽

ME Minshall ◽

WJ Valentine ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Hypoglycemic Agents ◽

Oral Hypoglycemic Agents ◽

Biphasic Insulin ◽

Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea

Value in Health ◽

10.1111/j.1524-4733.2009.00628.x ◽

2009 ◽

Vol 12 ◽

pp. S55-S61 ◽

Cited By ~ 6

Author(s):

Kyoung Hee Lee ◽

Se Jin Seo ◽

Jayne Smith-Palmer ◽

James L. Palmer ◽

Jeremy White ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

South Korea ◽

Human Insulin ◽

Insulin Aspart ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Short And Long-Term Cost-Effectiveness Of Switching Therapy From Biphasic Human Insulin 30 To Biphasic Insulin Aspart 30 In People With Type-2 Diabetes

Value in Health ◽

10.1016/j.jval.2013.03.819 ◽

2013 ◽

Vol 16 (3) ◽

pp. A164

Author(s):

P.D. Home ◽

P. Soewondo ◽

Z. Hussein ◽

A.A. Shafie ◽

K. AlRaddady ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Switching Therapy ◽

Short And Long Term

Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes

Current Medical Research and Opinion ◽

10.1185/03007991003689381 ◽

2010 ◽

Vol 26 (6) ◽

pp. 1399-1412 ◽

Cited By ~ 14

Author(s):

William J. Valentine ◽

Richard F. Pollock ◽

Juliette Plun-Favreau ◽

Jeremy White

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Aspart ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

The Cost

DB1 PROJECTED COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 IN TYPE 2 DIABETES PATIENTS SWITCHED FROM BIPHASIC HUMAN INSULIN IN THE UNITED STATES

Value in Health ◽

10.1016/s1098-3015(10)73111-9 ◽

2009 ◽

Vol 12 (3) ◽

pp. A10 ◽

Cited By ~ 1

Author(s):

M Aagren ◽

TL Thomsen ◽

VK Knudsen

Keyword(s):

United States ◽

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

The United States ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Letter to the Editor: Comments on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 vs insulin glargine in insulin naïve type 2 diabetes patients: cost effectiveness analysis in a UK setting

Current Medical Research and Opinion ◽

10.1185/030079906x104759 ◽

2006 ◽

Author(s):

Craig J. Currie ◽

Phil McEwan ◽

Chris Poole ◽

William J. Valentine ◽

Andrew J. Palmer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Effectiveness Analysis ◽

Cost Outcomes

PDB11 CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS: A MODELING ANALYSIS IN THE CHINESE SETTING

Value in Health ◽

10.1016/s1098-3015(11)73186-2 ◽

2010 ◽

Vol 13 (7) ◽

pp. A528

Author(s):

JL Palmer ◽

A Beaudet ◽

J White ◽

J Plun-Favreau ◽

J Smith-Palmer

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Insulin Glargine ◽

Insulin Aspart ◽

Biphasic Insulin ◽

Modeling Analysis ◽

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

BMC Endocrine Disorders ◽

10.1186/s12902-016-0116-8 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 4

Author(s):

Amir Farshchi ◽

Rokhsareh Aghili ◽

Maryam Oskuee ◽

Marjan Rashed ◽

Sina Noshad ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cost Effectiveness ◽

Human Insulin ◽

Insulin Aspart ◽

Effectiveness Study ◽

Regular Human Insulin ◽

Biphasic Insulin ◽

Cost Effectiveness Study